The New England Journal of Medicine Publishes Phase 3 Results for Tolvaptan in Patients with ADPKD
We are pleased to share some encouraging news regarding the treatment landscape for those living with ADPKD. Today, Otsuka announced results from their Phase 3 REPRISE trial of tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD). This data was presented at the American Society of Nephrology (ASN) Conference...